Literature DB >> 25635703

Contributions of the European trials (European randomized screening group) in computed tomography lung cancer screening.

Marjolein A Heuvelmans1, Rozemarijn Vliegenthart, Matthijs Oudkerk.   

Abstract

Lung cancer is the leading cause of cancer-related death worldwide. In 2011, the largest lung cancer screening trial worldwide, the US National Lung Screening Trial, published a 20% decrease in lung cancer-specific mortality in the computed tomography (CT)-screened group, compared with the group screened by chest x-ray. On the basis of this trial, different US guidelines recently have recommended CT lung cancer screening. However, several questions regarding the implementation of lung cancer screening need to be answered. In Europe, several lung cancer screening trials are ongoing. It is planned to pool the results of the lung cancer screening trials in European randomized lung cancer CT screening (EUCT). By pooling of the data, EUCT hopes to be able to provide additional information for the discussion of some important issues regarding the implementation of lung cancer screening by low-dose CT, including: the determination of the optimal screen population, the comparison between a volume-based and diameter-based nodule management protocol, and the determination of optimal screen intervals.

Entities:  

Mesh:

Year:  2015        PMID: 25635703     DOI: 10.1097/RTI.0000000000000135

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  9 in total

1.  Screening for Lung Cancer: Balancing Hope With Doubt About Applicability.

Authors:  Hans-Werner Hense
Journal:  Dtsch Arztebl Int       Date:  2015-09-18       Impact factor: 5.594

2.  Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe.

Authors:  Jesper Holst Pedersen; Witold Rzyman; Giulia Veronesi; Thomas A D'Amico; Paul Van Schil; Laureano Molins; Gilbert Massard; Gaetano Rocco
Journal:  Eur J Cardiothorac Surg       Date:  2017-03-01       Impact factor: 4.191

3.  Optimizing the lung cancer screening interval: the world is waiting.

Authors:  Carole A Ridge; Phillip M Boiselle
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 4.  Implementation and organization of lung cancer screening.

Authors:  Jesper Holst Pedersen; Haseem Ashraf
Journal:  Ann Transl Med       Date:  2016-04

5.  Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen.

Authors:  Nicola Sverzellati; M Silva; G Calareso; C Galeone; A Marchianò; S Sestini; G Sozzi; U Pastorino
Journal:  Eur Radiol       Date:  2016-02-11       Impact factor: 5.315

Review 6.  Implementing lung cancer screening in the real world: opportunity, challenges and solutions.

Authors:  Robert J Optican; Caroline Chiles
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 7.  [Prerequisites for a successful lung cancer screening program].

Authors:  N Becker; S Delorme
Journal:  Radiologe       Date:  2016-09       Impact factor: 0.635

8.  Challenges and research opportunities for lung cancer screening in China.

Authors:  Zixing Wang; Yuyan Wang; Yao Huang; Fang Xue; Wei Han; Yaoda Hu; Lei Wang; Wei Song; Jingmei Jiang
Journal:  Cancer Commun (Lond)       Date:  2018-06-07

9.  The Effect of Lung Volume on the Size and Volume of Pulmonary Subsolid Nodules on CT: Intraindividual Comparison between Total Lung Capacity and Tidal Volume.

Authors:  Hyunji Lee; Chansik An; Seok Jong Ryu
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-10-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.